Structure-based design of cyclin-dependent kinase inhibitors

Pharmacology and Therapeutics

Volumn 93, Issue 2-3, 2002, Pages 125-133

  Davies, Thomas G ^a,b   Pratt, David J ^a   Endicott, Jane A ^a   Johnson, Louise N ^a   Noble, Martin E M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

Activation; Cancer; CDK2; Cell cycle; Inhibitors; Structure based design

Indexed keywords

1 [9 ISOPROPYL 6 (4 METHOXYBENZYLIMINO) 9H PURIN 2 YL] 3 METHYLPENT 1 YN 3 OL; 2 AMINO 6 (PYRROLIDINON 5' YL)METHOXYPURINE; 2 AMINO 6 CYCLOHEXYLMETHYLOXY N 9 METHYLPURINE; 2,6 DIAMINO 4 CYCLOHEXYLMETHOXY 5 NITROSOPYRIMIDINE; 2,6 DIAMINO 4 CYCLOHEXYLMETHYLOXY 5 NITROSOPYRIMIDINE; 6 CYCLOHEXYLMETHOXYPURINE; 6 O CYCLOHEXYLMETHYLGUANINE; ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE INHIBITOR; NU 2017; NU 6032; NU 6052; O 6 CYCLOHEXYLMETHYLGUANINE; OL 567; UNCLASSIFIED DRUG; CDK2 PROTEIN, HUMAN; CDKN1C PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1C; ENZYME INHIBITOR; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE;

BINDING SITE; CANCER; CELL CYCLE; CONFERENCE PAPER; DRUG DESIGN; DRUG POTENCY; DRUG SPECIFICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EUKARYOTIC CELL; GENETIC LINKAGE; PATHOLOGY; PHOSPHORYLATION; PRIORITY JOURNAL; PROGNOSIS; X RAY CRYSTALLOGRAPHY; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; STRUCTURE ACTIVITY RELATION;

CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; HUMAN; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; CDC2-CDC28 KINASES; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P57; HUMANS;

EID: 0035990897     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00182-1     Document Type: Conference Paper

References (44)

1. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
2. Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs
3. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases
4. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
5. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
6. Initial sequencing and analysis of the human genome
7. Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate
8. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors
9. Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human cdk2 complexed with roscovitine
10. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
11. Crystal structure of cyclin-dependent kinase 2
12. Win some, lose some: Enthalpy-entropy compensation in weak intermolecular interactions
13. The regulation of E2F by pRb-family proteins
14. Cyclin-dependent kinases: Inhibition and substrate recognition
15. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
16. ATP-site directed inhibitors of cyclin-dependent kinases
17. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
18. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket
19. Genetic alterations of cyclins, cyclin-dependent kinases and Cdk inhibitors in human cancer
20. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification
21. The Rb/E2F pathway: Expanding roles and emerging paradigms
22. Indirubin, the active constitutent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases
23. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex
24. Cell-cycle regulators and cancer
25. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint
26. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2
27. P38 Mitogen-activated protein kinase inhibitors - Mechanisms and therapeutic potentials
28. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and a molecular structure of a CDK2-inhibitor complex
29. Chemical inhibitors of cyclin-dependent kinases
30. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent
31. Cyclin-dependent kinases: Engines, clocks and microprocessors
32. Chemical inhibitors of cyclin-dependent kinases: Insights into design from X-ray crystallographic studies
33. Staurosporine, a potentially important gift from a microorganism
34. Mechanisms of cyclin-dependent kinase regulation: Structure of cdks, their cyclin activators, and Cip and INK4 inhibitors
35. Structural basis of cyclin-dependent kinase activation by phosphorylation
36. Multiple modes of ligand recognition: Crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine
37. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: Bound waters and natural ligand as guides for inhibitor design
38. Preclinical and clinical development of cyclin-dependent kinase modulators
39. Anticancer drug targets: Cell cycle and checkpoint control
40. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket
41. The sequence of the human genome
42. Inhibition of cyclin-dependent kinases by purine analogues
43. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFβ and contact inhibition